Skip to main content

OPtimizing TArgets and Therapeutics In high risk and refractOry Multiple Myeloma

Ziel

Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. The MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenvironment (BMM). To target the essential components of this support system, it is the goal of the project to establish preclinical in vitro and in vivo models of MM that include functionally relevant elements of the BMM. The OPTATIO consortium will therefore analyse clinical data to correlate the presence of particular MM-BMM interactions with the pathogenesis of MM, with its intrinsic therapy resistance as well as with disease relapse due to the development of acquired drug resistance. These correlative data will be validated using autologous MM-BMM co-culture assays and reverse translated into in vitro screening and in vivo models, which will be subsequently used to develop lead compounds that target myeloma cells within their microenvironment.
The clinical expertise of several oncological divisions, the research experience of academic laboratories and the pharmaceutical know-how of small and medium sized enterprises as well as biotech industry joined their efforts within the OPTATIO consortium to drive this important development and to ensure translation towards clinical trials.
Expected impacts of the project include establishment of better diagnostics, new drug screening approaches for MM and novel personalised therapies based on individual ex vivo phenotyping leading to reduced patient mortality. Since envisaged drug screening methods are applicable to other areas of research and development, the project results will open new markets for industry partners in the fields of drug discovery and pharmaceutical development of products and services for personalized medicine.

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2011-two-stage
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

CP-FP - Small or medium-scale focused research project

Koordinator

MEDIZINISCHE UNIVERSITAT INNSBRUCK
Adresse
Christoph Probst Platz 1
6020 Innsbruck
Österreich
Aktivitätstyp
Higher or Secondary Education Establishments
EU-Beitrag
€ 510 700
Kontakt Verwaltung
Wolfgang Willenbacher (Dr.)

Beteiligte (11)

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Deutschland
EU-Beitrag
€ 287 956,80
Adresse
Josef-schneider-strasse 2
97080 Wurzburg
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Melanie Bauer (Ms.)
Masarykova univerzita
Tschechien
EU-Beitrag
€ 279 600
Adresse
Zerotinovo Namesti 9
60177 Brno Stred
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Sabina Sevcikova (Dr.)
UNIVERSITA DEGLI STUDI DI BARI ALDO MORO
Italien
EU-Beitrag
€ 262 800
Adresse
Piazza Umberto I 1
70121 Bari
Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Domenico Ribatti (Prof.)
DEL-PESTI CENTRUMKORHAZ-ORSZAGOS HEMATOLOGIAI ES INFEKTOLOGIAI INTEZET
Ungarn
EU-Beitrag
€ 144 000
Adresse
Nagyvarad Ter 1
1097 Budapest
Aktivitätstyp
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Kontakt Verwaltung
Tamás Masszi (Dr.)
VEREIN ZUR FOERDERUNG DER KREBSFORSCHUNG IN TIROL
Österreich
EU-Beitrag
€ 190 800
Adresse
Innrain 66
6020 Innsbruck
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Richard Greil (Prof.)
KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
Deutschland
EU-Beitrag
€ 319 792,50
Adresse
Breisacher Strasse 117
79106 Freiburg
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Michael Kubbutat (Dr.)
VICHEM CHEMIE KUTATO KFT
Ungarn
EU-Beitrag
€ 239 760
Adresse
Hermann Otto Utca 15
1022 Budapest
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Zoltán Dobai (Mr.)
ONCOTYROL-CENTER FOR PERSONALIZED CANCER MEDICINE GMBH
Österreich
EU-Beitrag
€ 293 040
Adresse
Karl Kapferer Strasse 5/3
6020 Innsbruck
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Lukas A. Huber (Prof.)
PHARMAMAR, S.A.
Spanien
EU-Beitrag
€ 239 880
Adresse
Avda. De Los Reyes , Poligono Industrial La Mina 1
28770 Colmenar Viejo (Madrid)
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Elena Calleja (Ms.)
THE BINDING SITE GMBH
Deutschland
EU-Beitrag
€ 37 200
Adresse
Robert-bosch-straße 2A
68723 Schwetzingen
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Silvia Kirchner (Dr.)
CENTER OF EXCELLENCE IN MEDICINE AND IT GMBH
Österreich
EU-Beitrag
€ 194 000
Adresse
Karl Kapferer Strasse 5
6020 Innsbruck
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Manuela Bock Bartl (Ms.)